Get the Stockscreener App
19.40
1.78%
0.34
Urogen Pharma Ltd stock is traded at $19.40, with a volume of 1.01M.
It is up +1.78% in the last 24 hours and up +49.00% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$19.06
Open:
$18.64
24h Volume:
1.01M
Relative Volume:
0.35
Market Cap:
$896.31M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-5.2861
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+2.37%
1M Performance:
+49.00%
6M Performance:
+76.20%
1Y Performance:
+22.63%
1-Day Range:
$18.48
$19.58
1-Week Range:
$18.37
$19.74
52-Week Range:
$3.42
$19.74
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
19.40 | 880.60M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Should I hold or sell UroGen Pharma Ltd. stock in 2025Financial News Forecasts For Smart Trading - jammulinksnews.com
How does UroGen Pharma Ltd. compare to its industry peersRetirement Planning Alerts That Work - jammulinksnews.com
Is UroGen Pharma Ltd. stock overvalued or undervaluedBreakout Stocks Strategy With Low Risk - jammulinksnews.com
What markets is FTAIN expanding into Is UroGen Pharma Ltd. stock a good long term investment optionChart Pattern Strategy To Watch Now - jammulinksnews.com
What is UroGen Pharma Ltd. company’s growth strategyStock Strategy Recommendation For Every Investor - jammulinksnews.com
What markets is UroGen Pharma Ltd. expanding into Is CPRX stock a good long term investment optionExpert Picks Forecasts Backed By Experts - jammulinksnews.com
UroGen Pharma Ltd. Could See a Relief Rally From SupportWatchlist for Low Risk High Return Stocks Updated - metal.it
UroGen Pharma Executives Sell Shares After Achieving Corporate Milestone - TradingView
Published on: 2025-07-30 03:03:07 - beatles.ru
What makes UroGen Pharma Ltd. stock price move sharplyLow Drawdown Real Time Trading Tips Shared - metal.it
Forecasting UroGen Pharma Ltd. price range with options dataReversal Alert Based on RSI Indicator Confirmed - metal.it
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 | URGN Stock News - GuruFocus
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 - GlobeNewswire
UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7 - Stock Titan
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology - Insider Monkey
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
What institutional investors are buying UroGen Pharma Ltd. stockSmart Portfolio Growth Plan That Work - jammulinksnews.com
UroGen Pharma Ltd. Tests 50 Day MA After Sharp DeclineProfit Focused Stock Screener Results Released - metal.it
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Re - GuruFocus
UroGen Pharma Announces Publication of Phase 3b Study on At-Home Administration of ZUSDURI™ for Bladder Cancer Treatment - Quiver Quantitative
UroGen’s bladder cancer treatment shows promise for home administration - Investing.com
UroGen Announces Publication of Phase 3b Study Results - GlobeNewswire
Revolutionary Home Treatment for Bladder Cancer Achieves 75% Response Rate in Clinical Trial - Stock Titan
Is UroGen Pharma Ltd. a growth stock or a value stockCapitalize on market momentum for maximum gains - jammulinksnews.com
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - Finansavisen
How does UroGen Pharma Ltd. generate profit in a changing economyDiscover high-growth stocks for your portfolio - jammulinksnews.com
How strong is UroGen Pharma Ltd. company’s balance sheetAchieve consistent profits with expert strategies - jammulinksnews.com
What is the risk reward ratio of investing in UroGen Pharma Ltd. stockFree Technical Analysis Support - jammulinksnews.com
What are analysts’ price targets for UroGen Pharma Ltd. in the next 12 monthsBuild a diversified portfolio for steady growth - jammulinksnews.com
Why UroGen Pharma Ltd. stock attracts strong analyst attentionChart Based Entries - metal.it
How UroGen Pharma Ltd. stock performs during market volatilityTechnical Breakout List - metal.it
Is UroGen Pharma Ltd. a good long term investmentSuperior trading gains - PrintWeekIndia
UroGen Pharma Ltd. Stock Analysis and ForecastExponential wealth increase - PrintWeekIndia
Urogen Pharma Ltd. shares fall 1.90% after-hours following Tyra Biosciences' special call on Achondroplasia. - AInvest
What analysts say about UroGen Pharma Ltd. stockFree Wealth Planning Blueprint - PrintWeekIndia
What drives UroGen Pharma Ltd. stock priceFree Advanced Stock Screener Access - PrintWeekIndia
UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance
UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Urogen Pharma Ltd Stock (URGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer |
Jul 28 '25 |
Sale |
19.14 |
5,149 |
98,552 |
158,229 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):